PIK3CA and cancer: In the phase III trial SOLAR-1, alpelisib improved the PFS in the cohort with PIK3CA-mutated cancer (11.7 months in the alpelisib-fulvestrant group versus 5.7 months in the placebo-fulvestrant group) [61].